Compass Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
CMPX$0.84+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
| For the Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(70,642) | $(50,773) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 64 | 259 |
| Share-based compensation | 13,902 | 6,543 |
| Amortization of premium and discount on marketable securities | (321) | (477) |
| ROU asset amortization | 1,068 | 843 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,526) | 4,804 |
| Accounts payable | 4,731 | 846 |
| Accrued expenses | 4,995 | 2,397 |
| Operating lease liability | (595) | (331) |
| Net cash used in operating activities | (48,324) | (35,889) |
| Cash flows from investing activities: | ||
| Purchase of property and equipment | (364) | (25) |
| Purchases of marketable securities | (90,975) | (167,082) |
| Proceeds from sale or maturities of marketable securities | 147,124 | 77,179 |
| Net cash provided by (used in) investing activities | 55,785 | (89,928) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock | — | 137,999 |
| Issuance costs from issuance of common stock | — | (8,638) |
| Proceeds from exercise of common stock | 3,854 | — |
| Taxes paid related to net shares settlement of RSUs | (489) | (815) |
| Net cash provided by financing activities | 3,365 | 128,546 |
| Net change in cash, cash equivalents and restricted cash | 10,826 | 2,729 |
| Cash, cash equivalents and restricted cash at beginning of period | 31,211 | 44,051 |
| Cash, cash equivalents and restricted cash at end of period | $42,037 | $46,780 |
| Reconciliation of cash, cash equivalents and restricted cash to the Condensed Consolidated Balance Sheets | ||
| Cash and cash equivalents | $41,469 | $46,212 |
| Restricted cash | 568 | $568 |
| Total cash, cash equivalents and restricted cash | $42,037 | $46,780 |
| Supplemental disclosure of cash flow information | ||
| Unrealized loss (gain) on marketable securities | $846 | $(64) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.